Stem definition | Drug id | CAS RN |
---|---|---|
neuromuscular blocking agents with rigid structure | 259 | 64228-79-1 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 0 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 8.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.65 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 0.10 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 5.70 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.52 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.31 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Nov. 23, 1983 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Anaphylactic shock | 569.72 | 43.29 | 147 | 2529 | 20127 | 46663259 |
Anaphylactic reaction | 236.50 | 43.29 | 95 | 2581 | 53017 | 46630369 |
Bronchospasm | 176.77 | 43.29 | 56 | 2620 | 15651 | 46667735 |
Hypotension | 175.06 | 43.29 | 127 | 2549 | 232462 | 46450924 |
Oliguria | 89.29 | 43.29 | 29 | 2647 | 8730 | 46674656 |
Tachycardia | 78.04 | 43.29 | 56 | 2620 | 99566 | 46583820 |
Cardiac arrest | 73.51 | 43.29 | 52 | 2624 | 90347 | 46593039 |
Pulseless electrical activity | 66.07 | 43.29 | 22 | 2654 | 7145 | 46676241 |
Circulatory collapse | 57.56 | 43.29 | 27 | 2649 | 21597 | 46661789 |
Shock | 57.29 | 43.29 | 27 | 2649 | 21818 | 46661568 |
Patent ductus arteriosus | 57.07 | 43.29 | 17 | 2659 | 3845 | 46679541 |
Infantile apnoea | 55.24 | 43.29 | 12 | 2664 | 764 | 46682622 |
Stress cardiomyopathy | 52.79 | 43.29 | 19 | 2657 | 7765 | 46675621 |
Foetal exposure during pregnancy | 51.33 | 43.29 | 28 | 2648 | 30719 | 46652667 |
Wrong product administered | 50.77 | 43.29 | 17 | 2659 | 5613 | 46677773 |
Ventricular fibrillation | 48.99 | 43.29 | 20 | 2656 | 11476 | 46671910 |
Post procedural complication | 46.09 | 43.29 | 21 | 2655 | 15708 | 46667678 |
Acute respiratory distress syndrome | 45.21 | 43.29 | 23 | 2653 | 21899 | 46661487 |
Foetal growth restriction | 44.42 | 43.29 | 16 | 2660 | 6551 | 46676835 |
Tonsillar hypertrophy | 43.62 | 43.29 | 10 | 2666 | 814 | 46682572 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Anaphylactic shock | 355.29 | 39.06 | 97 | 1930 | 13896 | 29936555 |
Bronchospasm | 190.89 | 39.06 | 56 | 1971 | 10282 | 29940169 |
Anaphylactic reaction | 189.40 | 39.06 | 71 | 1956 | 27911 | 29922540 |
Hypotension | 74.80 | 39.06 | 79 | 1948 | 200486 | 29749965 |
Circulatory collapse | 61.12 | 39.06 | 29 | 1998 | 20185 | 29930266 |
Oxygen saturation decreased | 54.89 | 39.06 | 35 | 1992 | 43405 | 29907046 |
Trigemino-cardiac reflex | 54.12 | 39.06 | 9 | 2018 | 111 | 29950340 |
Tachycardia | 42.37 | 39.06 | 37 | 1990 | 73702 | 29876749 |
Erythema | 40.80 | 39.06 | 37 | 1990 | 77414 | 29873037 |
Bradycardia | 39.91 | 39.06 | 34 | 1993 | 65492 | 29884959 |
Procedural hypotension | 39.80 | 39.06 | 10 | 2017 | 1015 | 29949436 |
Airway complication of anaesthesia | 39.46 | 39.06 | 7 | 2020 | 129 | 29950322 |
Source | Code | Description |
---|---|---|
ATC | M03AC04 | MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS Other quaternary ammonium compounds |
FDA EPC | N0000175720 | Nondepolarizing Neuromuscular Blocker |
FDA PE | N0000175732 | Neuromuscular Nondepolarizing Blockade |
CHEBI has role | CHEBI:48878 | agents antinicotiniques |
CHEBI has role | CHEBI:51371 | muscle relaxants |
MeSH PA | D018678 | Cholinergic Agents |
MeSH PA | D018680 | Cholinergic Antagonists |
MeSH PA | D009465 | Neuromuscular Agents |
MeSH PA | D009466 | Neuromuscular Blocking Agents |
MeSH PA | D003473 | Neuromuscular Nondepolarizing Agents |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D018733 | Nicotinic Antagonists |
MeSH PA | D018373 | Peripheral Nervous System Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Muscle relaxation, function | indication | 11977004 | |
General anesthesia | indication | 50697003 | |
Skeletal Muscle Relaxation for Endotracheal Intubation | indication | ||
Hypocalcemia | contraindication | 5291005 | |
Disorder of lung | contraindication | 19829001 | DOID:850 |
Hypokalemia | contraindication | 43339004 | |
Low blood pressure | contraindication | 45007003 | |
Eaton-Lambert syndrome | contraindication | 56989000 | DOID:0050214 |
Hypermagnesemia | contraindication | 66978005 | |
Myasthenia gravis | contraindication | 91637004 | DOID:437 |
Disorder of electrolytes | contraindication | 237840007 | |
Hypothermia | contraindication | 386689009 | |
Malignant hyperthermia | contraindication | 405501007 |
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Acetylcholine receptor | Ion channel | ANTAGONIST | IC50 | 7.77 | WOMBAT-PK | CHEMBL | |||
Neuronal acetylcholine receptor subunit alpha-2 | Ion channel | WOMBAT-PK | |||||||
Small conductance calcium-activated potassium channel protein 3 | Ion channel | Ki | 5.23 | CHEMBL |
ID | Source |
---|---|
2GQ1IRY63P | UNII |
4019619 | VUID |
N0000147713 | NUI |
D00758 | KEGG_DRUG |
64228-81-5 | SECONDARY_CAS_RN |
4018778 | VANDF |
4019619 | VANDF |
C0004234 | UMLSCUI |
CHEBI:2914 | CHEBI |
CHEMBL1360 | ChEMBL_ID |
CHEMBL1200527 | ChEMBL_ID |
DB13295 | DRUGBANK_ID |
DB00732 | DRUGBANK_ID |
D001279 | MESH_DESCRIPTOR_UI |
47319 | PUBCHEM_CID |
4734 | INN_ID |
9537 | IUPHAR_LIGAND_ID |
1218 | RXNORM |
1341 | MMSL |
397 | MMSL |
4228 | MMSL |
d00173 | MMSL |
002409 | NDDF |
013420 | NDDF |
372835000 | SNOMEDCT_US |
72752006 | SNOMEDCT_US |
74074008 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Atracurium Besylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1105 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 12 sections |
Atracurium Besylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1109 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 12 sections |
Atracurium Besylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-659 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 22 sections |
Atracurium Besylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-659 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 22 sections |
Atracurium Besylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-672 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 22 sections |
Atracurium Besylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-672 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 22 sections |
Atracurium Besylate | Human Prescription Drug Label | 1 | 55150-216 | INJECTION, SOLUTION | 50 mg | INTRAVENOUS | ANDA | 20 sections |
Atracurium Besylate | Human Prescription Drug Label | 1 | 55150-217 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 20 sections |
Atracurium Besylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-701 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 23 sections |
Atracurium Besylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-702 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 23 sections |